- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04294433
Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children
Clinical Trial to Assess Immunogenicity of 2 Versus 3 Doses of Hepatitis B Vaccines When Administered to Children Aged 2 to 18 Months
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the province of Quebec, Canada, hepatitis B vaccination of infants involves three doses of vaccine, 2, 4 and 18 months of age. However, in the current epidemiological context (virtual absence of new cases in young Quebecers) and taking into account scientific data which consistently show a high immunogenicity and efficacy of two doses of hepatitis B vaccine, the relevance of the second dose given at the age of 4 months is questionable.
this study is designed to compare the immunogenicity of the hepatitis B component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus (II) one dose of Infanrix-hexa and one dose of Twinrix administered respectively at 2 and 12 months of age versus (III) three doses of Infanrix-hexa administered at 2, 4 and 18 months of age (comparator).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1E7G9
- Recruiting
- Laval University Research Hospital Center
-
Contact:
- Vladimir Gilca, MD, PhD
- Phone Number: 510 4186667000
- Email: vladimir.gilca@inspq.qc.ca
-
Contact:
- Chantal Sauvageau, MD, MSc
- Phone Number: 368 4186667000
- Email: chantal.sauvageau@inspq.qc.ca
-
Principal Investigator:
- Vladimir Gilca, MD, PhD
-
Quebec, Canada, G1E7G9
- Recruiting
- Équipe de recherche en vaccination
-
Contact:
- Vladimir Gilca, MD, PhD
- Phone Number: 510 418 666 7000
- Email: vladimir.gilca@inspq.qc.ca
-
Contact:
- France Bouchard, RN
- Phone Number: 323 418 666 7000
- Email: france.bouchard@ssss.gouv.qc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Comparator group :
have received 3 doses of Infanrix-hexa as part of the regular vaccination program at the age of 2, 4 and 18 months.
• Study groups:
- have received 1 dose of Infanrix-hexa as part of the regular vaccination program at the age of 2 months.
Exclusion Criteria:
Have received other doses of hepatitis B vaccine;
- Be considered immunosuppressed;
- Have an autoimmune disease;
- Have contraindications to HBV vaccination, as defined in the Quebec Immunization Protocol;
- Have a bleeding disorder;
- Be significantly delayed in development;
- Have or plan to participate in other clinical studies with vaccines or products not approved in Canada;
- Have presented a serious clinical condition to the vaccines administered as part of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Infanrix-hexa+Infanrix-hexa+Infanrix-hexa
Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
|
Vaccines administrated according to product monographs' recommendations
|
Experimental: Infanrix-hexa+Infanrix-hexa
Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
|
Vaccines administrated according to product monographs' recommendations
|
Experimental: Infanrix-hexa+Twinrix
Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
|
Vaccines administrated according to product monographs' recommendations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity
Time Frame: 1 month post last dose of vaccine
|
The proportion of children with an anti-HBs titer ≥10mIU/ml
|
1 month post last dose of vaccine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune memory
Time Frame: 36 months post last primary vaccine dose
|
Immune response to a booster dose
|
36 months post last primary vaccine dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Study 11022017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
Clinical Trials on Infanrix-hexa, Twinrix-Junior
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis ABelgium, Czech Republic
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesEstonia, Germany, Spain
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bFinland
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b VaccinesFinland, Australia, Spain, Italy, Canada, Czechia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminatedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type bSlovakia
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis AAustralia, Belgium, Spain
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bCanada
-
MCM Vaccines B.V.Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi CompanyCompleted
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalVietnam